Journal
Multiple Sclerosis Journal
Publication Date
12-1-2023
Volume
29
Issue
14
First Page
1795
Last Page
1807
Document Type
Open Access Publication
DOI
10.1177/13524585231205708
Rights and Permissions
Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S. Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study. Mult Scler. 2023 Dec;29(14):1795-1807. doi: 10.1177/13524585231205708. Epub 2023 Oct 31. © The Author(s), 2023. Creative Commons License (CC BY-NC 4.0) This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
Recommended Citation
Singer, Barry A; Naismith, Robert T; and et al., "Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study." Multiple Sclerosis Journal. 29, 14. 1795 - 1807. (2023).
https://digitalcommons.wustl.edu/oa_4/2716
Department
ICTS (Institute of Clinical and Translational Sciences)
